FPAS
UTHR icon

Focus Partners Advisor Solutions’s United Therapeutics UTHR Stock Holding History

Focus Partners Advisor Solutions’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$795K Sell
1,467
-1,790
-55% -$1.01M 0.01% 650
2026
Q1 		$1.93M Sell
3,257
-879
-21% -$438K 0.02% 359
2025
Q4 		$2.02M Buy
4,136
+2,220
+116% +$1.03M 0.02% 309
2025
Q3 		$852K Buy
1,916
+476
+33% +$160K 0.01% 586
2025
Q2 		$414K Buy
+1,440
New +$430K 0.01% 733

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Focus Partners Advisor Solutions's UTHR Position: Q2 2026 in Review

Focus Partners Advisor Solutions reduced its United Therapeutics (UTHR) stake by 55% in Q2 2026, selling an estimated $1.01M and leaving 1,467 shares worth $795K. The position accounts for 0.01% of the portfolio, ranked #650.

Focus Partners Advisor Solutions first reported a position in UTHR in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.02M in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Focus Partners Advisor Solutions held 1,467 shares of United Therapeutics worth $795K as of Q2 2026.
  • Focus Partners Advisor Solutions sold 1,790 United Therapeutics shares in Q2 2026, an estimated $1.01M.
  • United Therapeutics made up 0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #650 holding.
  • Focus Partners Advisor Solutions first reported a position in United Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Focus Partners Advisor Solutions's United Therapeutics position peaked at $2.02M in Q4 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.